Citations

Clear

426 citation(s) found for "ST, Reza".

Urologic Manifestations of Hyperparathyroidism in Childhood
Malek, Reza S., Kelalis, Panayotis P.

Mayo Clinic

Journal of Urology | June 29, 2017 | Volume: 115 | Issue: 6 | Pages: 717-719

10.1016/s0022-5347(17)59347-7 | PMID 940210 Get It

Ureteropelvic Junction Obstruction. I. Observations on the Classic Type in Adults
Clark, William R. , Malek, Reza S.

Mayo Clinic

Journal of Urology | June 29, 2017 | Volume: 138 | Issue: 2 | Pages: 276-279

10.1016/s0022-5347(17)43118-1 | PMID 3599237 Get It

Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma
Xi, Mian , Hallemeier, Christopher L. , Merrell, Kenneth W. , Murphy, Mariela A. Blum, Ho, Linus, Hofstetter, Wayne L. , Mehran, Reza J. , Lee, Jeffrey H. , Weston, Brian , Komaki, Ritsuko , Ajani, Jaffer A. , Hallemeier, Christopher Leigh , Liao, Zhongxing , Murphy, Mariela Blum, Bhutani, Manoop S. , Maru, Dipen Maheshbhai , Lin, Steven H. , Ajani, Jaffer A

Mayo Clinic

Annals of Surgery | June 17, 2017 | Volume: 268 | Issue: 2 | Pages: 289-295

10.1097/sla.0000000000002352 | PMID 28628563 Get It

Objective: To discern recurrence risk stratification and investigate its influence on postoperative surveillance in patients with esophageal adenocarcinoma (EAC) after neoadjuvant chemoradiotherapy (CRT). Background: Reports documenting recurrence risk stratification in EAC after neoadjuvant CRT are scarce. Methods: Between 1998 and 2014, 601 patients with EAC who underwent neoadjuvant CRT followed by esophagectomy were included for analysis. The pattern, site, timing, and frequency of the first recurrence and potential prognostic factors for developing recurrences were analyzed. This cohort was used as the training set to propose a recurrence risk stratification system, and the stratification was further validated in another cohort of 172 patients. Results: A total of 150 patients (25.0%) achieved pathologic complete response (pCR) after neoadjuvant CRT and the rest were defined as the non-pCR group (n = 451) in the training cohort. After a median follow-up of 63.6 months, the pCR group demonstrated a significantly lower locoregional (4.7% vs 19.1%) and distant recurrence rate (22.0% vs.44.6%) than the non-pCR group (P < 0.001). Based on independent prognostic factors, patients were stratified into 4 recurrence risk categories: pCR with clinical stage I/II, pCR with clinical stage III, non-pCR with pN0, and non-pCR with pN+, with corresponding 5-year recurrence-free survival rates of 88.7%, 65.8%, 55.3%, and 33.0%, respectively (P < 0.001). The risk stratification was reproducible in the validation cohort. Conclusions: We proposed a recurrence risk stratification system for EAC patients based on pathologic response and pretreatment clinical stage. Risk-based postoperative surveillance strategies could be developed for different risk categories.
The 2016 American Orthopaedic Association-Japanese Orthopaedic Association Traveling Fellowship
Nandi, Sumon , Cho, Samuel K. , Freedman, Brett A. , Firoozabadi, Reza

Mayo Clinic

Journal of Bone and Joint Surgery | June 7, 2017 | Volume: 99 | Issue: 11 | Pages: e57

10.2106/jbjs.16.01152 | PMID 28590387 Get It

Abstract: The American Orthopaedic Association-Japanese Orthopaedic Association (AOA-JOA) Traveling Fellowship, which began in 1992 as a collaborative effort between the 2 orthopaedic communities, is aimed at fostering leadership among early-career surgeons through clinical, academic, and cultural exchange. Over 3 weeks, we experienced an extraordinary journey that led us across nearly 800 miles of the picturesque Japanese countryside, with stops at 6 distinguished academic centers. The opportunity to become personally acquainted with orthopaedic leaders in Japan, learn from their experiences, and immerse ourselves in the ancient and storied culture of a beautiful country was one that we will not soon forget. Along the way, we accumulated a wealth of information while enjoying the legendary hospitality of the Japanese people. There is a ubiquitous challenge in delivering cost-effective, accessible health care while maintaining a commitment to education and research. The U.S. orthopaedic community may take solace in the fact that our Japanese colleagues stand with us as partners in this pursuit, and our relationship with them continues to grow stronger through endeavors such as the AOA-JOA Traveling Fellowship. We look forward to honoring our Japanese colleagues in 2017 when we host them in the United States.
Comparative effectiveness of tumor response assessment methods: Standard-of-care versus computer-assisted response evaluation.
Florez, Edward , Sirous, Reza , Lirette, Seth T. , Griswold, Michael , Wang, Zhen J. , Bieszczad, Jacob, Cox, Kelly , Goenka, Ajit H. , Howard-Claudio, Candace M, Sanyal, Rupan , Henagen, J. Clark, Storrs, Judd , Allen, Brian C. , Remer, Erick M. , Howard, Candace M. , Kang, HyunSeon Christine , Nandwana, Sadhna B. , Shinagare, Atul Bhanudas , Davenport, Matthew S. , Rini, Brian I. , Smith, Andrew D. , Storrs, Judd M , Lirette, Seth

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 432-432

10.1200/jco.2017.35.6_suppl.432 Get It

432 Background: In clinical trials and clinical practice, tumor response assessment with computed tomography (CT) defines critical end points in patients with metastatic disease treated with systemic agents. Methods to reduce errors and improve efficiency in tumor response assessment could improve patient care. Methods: Eleven readers from 10 different institutions independently categorized tumor response according to three different therapeutic response criteria using paired baseline and initial post-therapy CT studies from 20 randomly selected patients with metastatic renal cell carcinoma treated with sunitinib as part of a completed phase III multi-institutional study. Images were evaluated with a manual tumor response evaluation method (standard-of-care) and with computer-assisted response evaluation (CARE) that included stepwise guidance, interactive error-identification and correction methods, automated tumor metric extraction, calculations, response categorization, and data/image archival. A cross-over design, patient randomization, and two-week washout period were used to reduce recall bias. Comparative effectiveness metrics included error rate and mean patient evaluation time. Results: The standard-of-care method was on average associated with one or more errors in 30.5% (6.1/20) of patients while CARE had a 0.0% (0.0/20) error rate (p<0.001). The most common errors were related to data transfer and arithmetic calculation. In patients with errors, the median number of error types was 1 (range 1-3). Mean patient evaluation time with CARE was twice as fast as the standard-of-care method (6.4 vs. 13.1 minutes, p<0.001). Conclusions: Computer-assisted tumor response evaluation reduced errors and time of evaluation, indicating better overall effectiveness than manual tumor response evaluation methods that are the current standard-of-care.
Human Gongylonema pulchrum Infection: Esophageal Symptoms and Need for Prolonged Albendazole Therapy
Reza, Mohammed, Peterson, Joy H., Hata, D. Jane , Libertin, Claudia R. , Lewis, Jason

Mayo Clinic

The American Society of Tropical Medicine and Hygiene | January 31, 2017 | Volume: 96 | Issue: 4 | Pages: 873-875

10.4269/ajtmh.16-0852 | PMID 28138043 Get It

We describe a case of human infection with Gongylonema pulchrum acquired in southeast Georgia. The patient presented with intermittent yet persistent nausea and vomiting for months. This case describes the need for extraction of worms on two occasions each followed by courses of albendazole treatment. Gongylonema pulchrum infections with high worm burden may relapse after extraction of the worm and a 3-day short course of albendazole therapy. Longer courses of albendazole may be indicated in selected circumstances.
DisseminatedMycobacterium interjectumInfection with Bacteremia, Hepatic and Pulmonary Involvement Associated with a Long-Term Catheter Infection
Sotello, David , Hata, D. Jane , Reza, Mohammed, Satyanarayana, Raj, Arunthari, Vichaya, Bosch, Wendelyn , Sotello Aviles, David A

Mayo Clinic

Case Reports in Infectious Diseases | January 18, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-5

10.1155/2017/6958204 | PMID 28197350 Get It

We present a 49-year-old female with one year of intermittent fevers, chills, night sweats, and significant weight loss. Liver and lung biopsy showed evidence of a granulomatous process. Blood and liver biopsy cultures yielded growth of presumedMycobacterium interjectum, thought to be related to a disseminated long-term central venous catheter infection. She successfully received one year of combined antimicrobial therapy after catheter removal without recurrence of disease.M. interjectumhas been previously described as a cause of lymphadenitis in healthy children and associated with pulmonary disease in adults, although other localized infections have been reported. This is the first case described of a disseminatedM. interjectuminfection with bacteremia, hepatic and pulmonary involvement associated with a long-term catheter infection.
Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell–like spheroids, and tumor xenografts through multiple cell signaling pathways
Bijangi‐Vishehsaraei, Khadijeh , Saadatzadeh, M. Reza , Nguyen, Angie, Kamocka, Malgorzata M. , Cai, Wenjing , Cohen‐Gadol, Aaron , Halum, Stacey L. , Pollok, Karen E. , Safa, Ahmad R., Wang, Haiyan , Cai, Wenjing, Sarkaria, Jann N.

Mayo Clinic

Journal of Neurosurgery | January 6, 2017 | Volume: 127 | Issue: 6 | Pages: 1219-1230

10.3171/2016.8.jns161197 | PMID 28059653 Get It

OBJECTIVE Defects in the apoptotic machinery and augmented survival signals contribute to drug resistance in glioblastoma (GBM). Moreover, another complexity related to GBM treatment is the concept that GBM development and recurrence may arise from the expression of GBM stem cells (GSCs). Therefore, the use of a multifaceted approach or multitargeted agents that affect specific tumor cell characteristics will likely be necessary to successfully eradicate GBM. The objective of this study was to investigate the usefulness of sulforaphane (SFN)—a constituent of cruciferous vegetables with a multitargeted effect—as a therapeutic agent for GBM. METHODS The inhibitory effects of SFN on established cell lines, early primary cultures, CD133-positive GSCs, GSC-derived spheroids, and GBM xenografts were evaluated using various methods, including GSC isolation and the sphere-forming assay, analysis of reactive oxygen species (ROS) and apoptosis, cell growth inhibition assay, comet assays for assessing SFN-triggered DNA damage, confocal microscopy, Western blot analysis, and the determination of in vivo efficacy as assessed in human GBM xenograft models. RESULTS SFN triggered the significant inhibition of cell survival and induced apoptotic cell death, which was associated with caspase 3 and caspase 7 activation. Moreover, SFN triggered the formation of mitochondrial ROS, and SFN-triggered cell death was ROS dependent. Comet assays revealed that SFN increased single- and double-strand DNA breaks in GBM. Compared with the vehicle control cells, a significantly higher amount of γ-H2AX foci correlated with an increase in DNA double-strand breaks in the SFN-treated samples. Furthermore, SFN robustly inhibited the growth of GBM cell–induced cell death in established cell cultures and early-passage primary cultures and, most importantly, was effective in eliminating GSCs, which play a major role in drug resistance and disease recurrence. In vivo studies revealed that SFN administration at 100 mg/kg for 5-day cycles repeated for 3 weeks significantly decreased the growth of ectopic xenografts that were established from the early passage of primary cultures of GBM10. CONCLUSIONS These results suggest that SFN is a potent anti-GBM agent that targets several apoptosis and cell survival pathways and further preclinical and clinical studies may prove that SFN alone or in combination with other therapies may be potentially useful for GBM therapy.
Atypical case of perimesencephalic subarachnoid hemorrhage
Malhotra, Konark , Magaki, Shino , Sillero, Maria Inmaculada Cobos, Vinters, Harry V. , Jahan, Reza, Brown, Robert D. , Liebeskind, David S. , Liebeskind, David S.

Mayo Clinic

Neuropathology | December 7, 2016 | Volume: 37 | Issue: 3 | Pages: 272-274

10.1111/neup.12358 | PMID 27925301 Get It

Perimesencephalic subarachnoid hemorrhage (PM‐SAH) refers to intracranial hemorrhage located in the perimesencephalic cistern. The etiology remains mainly unclear, although venous leakage or rupture has been postulated. We report an interesting case of a 57‐year‐old healthy man who presented initially with PM‐SAH with worsening of subcortical lesions on follow‐up neuroimaging. Histopathological examination demonstrated cerebral amyloid angiopathy with perivascular inflammation.
NPR3 protects cardiomyocytes from apoptosis through inhibition of cytosolic BRCA1 and TNF-α
Izadpanah, Reza , Braun, Stephen E. , Alt, Eckhard , Lin, Dong , Chai, Yubo, Chai, Yubo

Mayo Clinic

Cell Cycle | August 5, 2016 | Volume: 15 | Issue: 18 | Pages: 2414-2419

10.1080/15384101.2016.1148843 | PMID 27494651 Get It